ASCO 2026 | Neoadjuvant CTLA-4, PD-1, and LAG-3 blockade improves NPS in melanoma
Ahmad Tarhini, MD, PhD, Moffit Cancer Center, Tampa, FL, discusses the improvement in neuropathy-free survival (NPS) rates in a Phase II trial (NCT06295159) of neoadjuvant ipilimumab, nivolumab, and relatlimab in resectable melanoma. A new expansion cohort has been initiated to further validate these findings and a Phase III study is also warranted to prospectively confirm these results. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This is certainly an improvement in the field as we see the improvement in the NPS rates up to 74% or so. And therefore, as a next step, we have now started a new expansion cohort to further validate these data. But we believe also considering definitive testing in the context of a randomized phase 3 study is warranted. So clearly we have to test this prospectively in a randomized setting, but that is promising...
This is certainly an improvement in the field as we see the improvement in the NPS rates up to 74% or so. And therefore, as a next step, we have now started a new expansion cohort to further validate these data. But we believe also considering definitive testing in the context of a randomized phase 3 study is warranted. So clearly we have to test this prospectively in a randomized setting, but that is promising.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
